Internship

Intern – Dmpk

Confirmed live in the last 24 hours

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Biotechnology
Healthcare

Compensation Overview

$22 - $45Hourly

San Bruno, CA, USA

This is a paid internship at our South San Francisco headquarters.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Requirements
  • Have completed two to four years at a US college or university at the time of the program
  • Have a GPA of at least 3.0 (4.0 scale)
  • Seeking a BS/MS/PhD degree or a career in fields related to the pharmaceutical industry (e.g., drug metabolism, pharmacokinetics, toxicology, analytical chemistry)
  • Experience in general laboratory techniques, organic chemistry, biochemistry, liquid chromatography, mass spectrometry, and general laboratory safety practices preferred
Responsibilities
  • Assist senior staff in the design, implementation, interpretation, and instrumental techniques related to the characterization of drug metabolism.
  • Apply in vitro drug metabolism techniques toward the prediction of potential drug toxicity and the rate of drug metabolism in vivo.
  • Gain expertise in the general strategy of LC/MS method development for small molecule drugs.
  • Maintain accurate records of ongoing projects and laboratory records in adherence with documentation standards.
  • Conduct independent literature reviewing in support of these studies.
  • Take part in Internship Seminars and Social Events
  • Preparation of an Internship Program Final Presentation.

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, depending on the condition being treated. For example, they are working on drugs for heart failure, hypertrophic cardiomyopathy, amyotrophic lateral sclerosis, and spinal muscular atrophy. What sets Cytokinetics apart from competitors is their specific focus on muscle-related conditions and their extensive pipeline of drugs currently in clinical trials. The company's goal is to bring effective treatments to market that address the unmet needs of patients suffering from these debilitating diseases.

Company Stage

IPO

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

2%

1 year growth

1%

2 year growth

15%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful Phase III trial results for aficamten in treating obstructive hypertrophic cardiomyopathy (HCM) highlight the company's potential for market leadership in this area.
  • The $575M funding from Royalty Pharma ensures strong financial support for the commercial launch of aficamten and further R&D activities.
  • Recent investments and stock offerings indicate strong investor confidence and provide additional capital for growth and development.

What critics are saying

  • The late-stage biopharmaceutical market is highly competitive, with significant pressure to bring drugs to market quickly and efficiently.
  • Dependence on the success of clinical trials and regulatory approvals poses inherent risks, as any setbacks could delay commercialization and revenue generation.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle function improvement for cardiovascular and neuromuscular diseases, a niche area with high unmet medical needs.
  • The company has a robust pipeline of small molecule muscle activators and inhibitors, setting it apart from competitors with more generalized drug portfolios.
  • Strategic funding collaborations, such as the $575M deal with Royalty Pharma, provide significant financial backing for their R&D and commercialization efforts.

Help us improve and share your feedback! Did you find this helpful?